 |
|||
 |
 |
 |
|
PSMA Monoclonal Antibodies
PSMA ADC is a fully human monoclonal antibody to PSMA linked to a derivative of auristatin, a highly potent cytotoxic drug, utilizing Seattle Genetics' proprietary ADC technology. The monoclonal antibody portion binds PSMA with high affinity and specificity, thereby targeting the cytotoxic drug to cancer cells. 
After binding its target, PSMA ADC rapidly enters the cancer cell and releases the drug payload. Once released from the antibody, the drug destroys the cancer cell by disrupting the cellular "backbone" required for growth and division. PSMA ADC is designed to be stable in blood so as to minimize toxicity to normal cells and tissues that do not express PSMA.
In a mouse model of human prostate cancer PSMA monoclonal antibody substantially reduced tumor growth. In this animal model of human prostate cancer, PSMA antibody-drug conjugate (ADC) significantly prolonged overall survival up to nine-fold as compared to untreated animals. Established tumors in two of the five animals treated at the highest dose were eradicated and remained undetectable over 500 days through the completion of the study. No overt evidence of toxicity was observed in any of these animal model tests.